Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 11/20 | 0.67 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | ICMT | O60725 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31568445 | 0.89 | MRGPRX4 (0.76) | MRGPRX4SLC6A4GRM5PDCD1CD274 | |
| SCHEMBL22469778 | 0.89 | MRGPRX4 (0.76) | MRGPRX4SLC6A4GRM5PDCD1CD274 | |
| SCHEMBL4197074 | 0.85 | MRGPRX4 (0.71) | MRGPRX4ARSLC6A4 | |
| SCHEMBL26162620 | 0.81 | MRGPRX4 (0.68) | MRGPRX4MAOB | |
| SCHEMBL22480554 | 0.81 | MRGPRX4 (1.00) | MRGPRX4SLC6A4GRM5 | |
| SCHEMBL23235825 | 0.80 | MAOB (0.65) | GRM5MAOB | |
| SCHEMBL22481083 | 0.80 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL22480884 | 0.79 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL12173115 | 0.79 | MRGPRX4 (0.58) | MRGPRX4MAOB | |
| SCHEMBL14854689 | 0.78 | MRGPRX4 (0.76) | MRGPRX4SLC6A4PDCD1CD274HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| EP-1915338-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | MRGPRX4 1139/4885AR 1/4885ICMT 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.